Charging Ahead: How U.S. Tariffs on Chinese EVs Will Impact the Market

The United States government has fired a major salvo in the escalating electric vehicle (EV) battleground with China, slapping heavy tariffs on Chinese EV imports as well as key battery materials and components. While the move aims to protect American jobs and manufacturers, it carries significant implications for automakers, suppliers, and investor portfolios on both sides of the Pacific.

At the center of the new trade barriers is a 100% tariff on Chinese-made EVs entering the U.S. market. The administration has also imposed 25% duties on lithium-ion batteries, battery parts, and critical minerals like graphite, permanent magnets, and cobalt used in EV production.

For American automakers like Tesla, General Motors, and Ford, the tariffs could provide a substantial competitive advantage on home soil. By erecting steep import costs on Chinese EVs, it makes their domestically produced electric models immediately more price competitive versus foreign rivals. This pricing edge could help ramp up EV sales for Detroit’s Big Three as they work to gain traction in this burgeoning market.

The tariffs represent a major headache for Chinese automakers like BYD that have ambitions to crack the lucrative U.S. EV market. BYD and peers like Nio have been counting on American sales to drive their global expansion efforts. The 100% tariff makes their EVs essentially uncompetitive on price compared to domestic alternatives.

However, the calculus could change if Chinese EV makers ramp up battery production and vehicle assembly closer to U.S. shores. BYD has already established a manufacturing footprint in Mexico. If more production is localized in North America, Chinese brands may be able to circumvent the duties while realizing lower logistics costs.

The impacts extend beyond just automakers. Battery material suppliers and lithium producers could face production cuts and lower pricing if Chinese EV demand softens due to fewer exports heading stateside. Major lithium producers like Albemarle and SQM saw shares dip as the tariff news increased global oversupply fears.

But if U.S. electric vehicle adoption accelerates in response to the import barriers, it could create new demand for lithium and other battery materials from domestic sources, analysts note. North American miners and processors may emerge as beneficiaries as automakers look to localize their supply chains.

Of course, trade disputes cut both ways. There are risks that China could retaliate against major U.S. exports or American companies operating in the country. That creates potential headwinds for a wide range of U.S. multinationals like Apple, Boeing, and Starbucks that rely on Chinese production and consumption. Any tit-for-tat actions could ripple across the global economy.

The levies also raise costs across EV supply chains at a vulnerable time. With inflation already depressing consumer demand, pricier batteries and components could curb the pace of electrification both in the U.S. and globally if passed along to car buyers. Conversely, domestic automakers have leeway to absorb higher input expenses to gain market share from Chinese imports.

With EV competition heating up between the world’s two largest economies, investors will need to scrupulously analyze potential winners and losers from the unfolding trade battle across the electric auto ecosystem. In the near-term, the tariffs appear to boost American legacy automakers while putting China’s crop of upstart EV makers on the defensive. Global battery and mineral suppliers face an uncertain shake-up.

Over the longer haul, costs, capital outlays, production geography, and consumer demand dynamics will ultimately determine the fallout’s enduring market impacts. The new levies represent a double-edged sword potentially accelerating the EV transition in the U.S. while fracturing previously integrated cross-border supply lines.

Prudent investors should weigh both the risks and opportunities across the entire EV value chain. While headline-grabbing, tariffs alone won’t determine winners and losers in the seismic shift to electric mobility taking shape globally. Proactively adjusting portfolios to the changing landscape will be crucial for optimizing exposures.

Want small cap opportunities delivered straight to your inbox?

Channelchek’s free newsletter will give you exclusive access to our expert research, news, and insights to help you make informed investment decisions.

Get Instant Access

Release – Salem Media Group Announces New West Region Digital Sales Director Christian Kligora

Research News and Market Data on SALM

CAMARILLO, Calif.–(BUSINESS WIRE)– Salem Media Group, Inc. (OTCQX: SALM) announced Christian Kligora as the new West Region Digital Sales Director on its digital marketing firm, Salem Surround.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240523736968/en/

Christian Kligora (Photo: Business Wire)

Christian brings a wealth of digital marketing and operational experience to Salem with his work for Marketron where he served in an executive leadership position driving business development. Prior to that, Christian had over a decade of building teams and driving revenue and operational growth for Gannett’s Local IQ and its predecessor, ReachLocal where he oversaw the growth and management of many local and regional offices.

Jon Latzer, Vice President, General Manager of Salem Surround, said, “Christian Kligora is a generational find and will help Salem Surround achieve both revenue growth and help with operational efficiencies. We are excited to have him join our expanding team while leading our Western Region to new heights of success.”

“I’m excited to join the fantastic team at Salem Media,” said Christian Kligora. “Joining Salem represents a unique opportunity to contribute to a media landscape that values integrity, innovation, and impact. I am eager to partner with our linear/digital sales teams to explore innovative ways to connect with our audience.”

Christian is based in Denver where he lives with his wife Angela.

ABOUT SALEM MEDIA GROUP:

Salem Media Group is America’s leading multimedia company specializing in Christian and conservative content, with media properties comprising radio, digital media and book and newsletter publishing. Each day Salem serves a loyal and dedicated audience of listeners and readers numbering in the millions nationally. With its unique programming focus, Salem provides compelling content, fresh commentary and relevant information from some of the most respected figures across the Christian and conservative media landscape. Learn more about Salem Media Group, Inc. at www.salemmedia.com.

Evan D. Masyr
Executive Vice President and Chief Financial Officer
(805) 384-4512
evan@salemmedia.com

Source: Salem Media Group, Inc.

Released May 28, 2024

Release – Ocugen Set to Join Russell 3000® Index Effective June 28, 2024

Research News and Market Data on OCGN

MALVERN, Pa., May 28, 2024 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced its expected upcoming inclusion in the Russell 3000® Index, according to preliminary Russell reconstruction information posted on the FTSE Russell website. The newly reconstructed index will take effect after the market closes on June 28, 2024.

“Inclusion of Ocugen to the Russell 3000® Index is our latest milestone, adding to what has already been a transformational year for the Company with three of our game-changing modifier gene therapies targeting blindness diseases—both rare and those affecting millions—in clinical trials,” said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. “This ranking signifies the value of our pipeline, including the recently initiated Phase 3 liMeliGhT clinical trial of OCU400 for broad retinitis pigmentosa, and robust growth strategy, supporting our efforts to enable long-term shareholder value, garner significant visibility of Ocugen within the investment community, and broaden our shareholder base.”

The annual Russell 3000® Index reconstitution measures the performance of the largest 3,000 U.S. companies representing approximately 96% of the investable U.S. equity market as of Tuesday, April 30.

Membership in the U.S. Russell 3000® remains in place for one year and means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Russell’s U.S. indexes serve as the benchmark for about $10.5 trillion in assets as of the close of December 2023. Russell indexes are part of FTSE Russell, a leading global index provider.

About FTSE Russell:
FTSE Russell is a leading global provider of benchmarking, analytics, and data solutions for investors, giving them a precise view of the market relevant to their investment process. A comprehensive range of reliable and accurate indexes provides investors worldwide with the tools they require to measure and benchmark markets across asset classes, styles, or strategies.

FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products, and index-based derivatives.

FTSE Russell is focused on applying the highest industry standards in index design and governance, employing transparent rules-based methodology informed by independent committees of leading market participants. FTSE Russell fully embraces the IOSCO Principles, and its Statement of Compliance has received independent assurance. Index innovation is driven by client needs and customer partnerships, allowing FTSE Russell to continually enhance the breadth, depth and reach of its offering.

FTSE Russell is wholly owned by London Stock Exchange Group. For more information, visit: https://www.lseg.com/en/ftse-russell.

About Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patient’s lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. Discover more at www.ocugen.com and follow us on X and LinkedIn.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the Company’s expected inclusion in the Russell 3000 ® Index, qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including, but not limited to, the risks that changes may be made to the preliminary Russell reconstruction lists prior to finalization, that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical data and testing of may not be predictive of the results or success of later clinical trials; and that that clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Contact:
Tiffany Hamilton
Head of Communications
Tiffany.Hamilton@ocugen.com

Release – Orion Group Holdings Set to Join the Russell 3000® Index

Research News and Market Data on ORN

HOUSTON, May 28, 2024 (GLOBE NEWSWIRE) — Orion Group Holdings, Inc. (NYSE: ORN) (the “Company”), a leading specialty construction company, today announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell indexes annual reconstitution, effective after the US market opens on July 1, 2024, according to a preliminary list of additions posted May 24, 2024.

Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of April 30, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

“Being included in the Russell Index is an important milestone for Orion and reflects the significant progress we have made transforming the business throughout 2023. Our inclusion in the Russell Index should help expand investor awareness, increase institutional ownership, and provide additional liquidity in our stock,” said Travis Boone, Chief Executive Officer of Orion Group Holdings, Inc. “This milestone was achieved during an exciting time for Orion. With a strong foundation of operational discipline, a vastly improved business development team and a healthy balance sheet, we have set the Company up for success and are focused on driving growth for the remainder of 2024 and beyond.”

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to the data as of the end of December 2023, about $10.5 trillion in assets are benchmarked against Russell’s US indexes, which belong to FTSE Russell, a prominent global index provider.

About Orion Group Holdings

Orion Group Holdings, Inc., a leading specialty construction company serving the infrastructure, industrial and building sectors, provides services both on and off the water in the continental United States, Alaska, Hawaii, Canada and the Caribbean Basin through its marine segment and its concrete segment. The Company’s marine segment provides construction and dredging services relating to marine transportation facility construction, marine pipeline construction, marine environmental structures, dredging of waterways, channels and ports, environmental dredging, design and specialty services. Its concrete segment provides turnkey concrete construction services including place and finish, site prep, layout, forming, and rebar placement for large commercial, structural and other associated business areas. The Company is headquartered in Houston, Texas with regional offices throughout its operating areas. The Company’s website is located at: https://www.oriongroupholdingsinc.com.

Forward-Looking Statements

The matters discussed in this press release may constitute or include projections or other forward-looking statements within the meaning of the “safe harbor” provisions of Section 27A of the Securities Exchange Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, of which provisions the Company is availing itself. Certain forward-looking statements can be identified by the use of forward-looking terminology, such as ‘believes’, ‘expects’, ‘may’, ‘will’, ‘could’, ‘should’, ‘seeks’, ‘approximately’, ‘intends’, ‘plans’, ‘estimates’, or ‘anticipates’, or the negative thereof or other comparable terminology, or by discussions of strategy, plans, objectives, intentions, estimates, forecasts, outlook, assumptions, or goals. In particular, statements regarding future operations or results, including those set forth in this press release, and any other statement, express or implied, concerning future operating results or the future generation of or ability to generate revenues, income, net income, gross profit, EBITDA, Adjusted EBITDA, Adjusted EBITDA margin, or cash flow, including to service debt or maintain compliance with debt covenants, and including any estimates, forecasts or assumptions regarding future revenues or revenue growth, are forward-looking statements. Forward-looking statements also include project award announcements, estimated project start dates, anticipated revenues, and contract options which may or may not be awarded in the future. Forward-looking statements involve risks, including those associated with the Company’s fixed price contracts that impacts profits, unforeseen productivity delays that may alter the final profitability of the contract, cancellation of the contract by the customer for unforeseen reasons, delays or decreases in funding by the customer, levels and predictability of government funding or other governmental budgetary constraints, and any potential contract options which may or may not be awarded in the future, and are at the sole discretion of award by the customer. Past performance is not necessarily an indicator of future results. Considering these and other uncertainties, the inclusion of forward-looking statements in this press release should not be regarded as a representation by the Company that the Company’s plans, estimates, forecasts, goals, intentions, or objectives will be achieved or realized. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update information contained in this press release whether as a result of new developments or otherwise, except as required by law.

Please refer to the Company’s 2023 Annual Report on Form 10-K, filed on March 1, 2024 which is available on its website at www.oriongroupholdingsinc.com or at the SEC’s website at www.sec.gov, for additional and more detailed discussion of risk factors that could cause actual results to differ materially from our current expectations, estimates or forecasts.

Contacts:
Financial Profiles, Inc.
Margaret Boyce 310-622-8247
orn@finprofiles.com 

Russell Reconstitution 2024: The Ultimate Guide to This Year’s Index Shake-Up

The annual Russell reconstitution is one of the biggest events in the investing world, shaping the composition of the widely followed Russell indexes, including the influential Russell 2000 and Russell 3000 indexes. This comprehensive process ensures these indexes accurately represent various U.S. market segments by reflecting changes in company market capitalizations and characteristics.

What is the Russell Reconstitution?
The Russell reconstitution is an annual rebalancing process where all Russell equity indexes undergo a complete overhaul. During reconstitution, the index provider FTSE Russell rebuilds the Russell indexes from the ground up based on new data on eligible stocks’ market caps, trading volumes, and other criteria.

This vital event maintains the integrity of Russell indexes as accurate benchmarks by updating their holdings to reflect the current landscape of the U.S. stock market. Reconstitution allows companies that have grown or shrunk in value to be properly represented in the appropriate Russell indexes.

The Importance of the Russell 3000 Index
A major focus of the reconstitution is the Russell 3000 Index, considered one of the leading benchmarks for the overall U.S. equity market. This index aims to capture 98% of U.S. stocks by market cap.

On May 24, 2024, FTSE Russell published its annual reconstitution updates, revealing notable new additions to the Russell 3000 like Ocugen, Eledon Pharmaceuticals, NN Inc., and Bitcoin Depot. Such changes highlight how reconstitution allows the index to evolve with the market.

The Closely Watched Russell 2000 Index
Another keenly watched Russell index is the small-cap Russell 2000, which tracks the smallest 2,000 companies in the Russell 3000 by market cap. This index is considered a leading benchmark for small-cap U.S. stocks.

During reconstitution, companies can move in or out of the Russell 2000 based on changes to their market capitalization or investment style exposures like value vs growth. This rebalancing ensures the Russell 2000 precisely represents today’s small-cap universe.

IPO Additions Throughout the Year
In addition to the annual reset, FTSE Russell regularly adds eligible IPO stocks to its indexes on a quarterly basis. This allows newly public companies to quickly enter major benchmarks like the Russell 3000 instead of waiting for reconstitution.

Russell’s IPO treatment distinguishes between fully underwritten IPOs and partial or “best efforts” public offerings when determining appropriate share weights and eligibility.

Rebalancing Drives Major Trading Activity
Russell reconstitution is a major trading event, as index funds and ETFs tracking Russell benchmarks must rebalance their portfolios to match updated index constituents and weightings.

Estimates suggest hundreds of billions in assets follow the Russell benchmarks, meaning their reconstitution announcements can trigger massive shifts in demand for newly added or removed stocks.

Following Russell’s Transparent Methodology
FTSE Russell’s reconstitution process follows an objective, rules-based methodology spelled out in publicly available documentation. Key eligibility factors include:

  • Trading on eligible U.S. stock exchanges
  • Meeting minimum price, market cap, and liquidity thresholds
  • Sufficient public share float and voting rights
  • Eligible corporate structures like public operating companies

Staying on top of Russell’s transparent reconstitution rules allows investors to understand how index changes may impact their portfolios and positions.

The Russell Reconstitution’s Continuing Impact
As indexes like the Russell 3000 continue gaining prominence as core portfolio benchmarks, Russell reconstitution’s influence grows. The 2024 event reinforces the Russell indexes’ role in definitively capturing U.S. market performance by surgery evolving index holdings to match current realities.

Whether reallocating client assets, developing new index funds, or simply understanding market composition changes, the 2024 Russell reconstitution guide will prove essential reading for investors. Follow this yearly event closely, as it shapes the benchmarks driving U.S. equity allocations for years to come.

Upcoming 2024 Russell Reconstitution Schedule

Friday, May 31st, June 7th, 14th, and 21st – Preliminary membership lists (reflecting any updates) posted to the FTSE Russell website after 6PM US eastern time.

Monday, June 10th – “Lock-down” period begins with the updates to reconstitution membership considered to be final.

Friday, June 28th – Russell Reconstitution is final after the close of the US equity markets.

Monday, July 1st – Equity markets open with the newly reconstituted Russell US Indexes.

Bitcoin Mining Showdown: Riot Platforms’ Power Play for Bitfarms

In a bold move that could significantly reshape the cryptocurrency mining industry, Riot Platforms Inc. has made an unsolicited offer to acquire rival Bitcoin miner Bitfarms Ltd. for $950 million. This acquisition bid, which includes both cash and stock, values Bitfarms at $2.30 per share, a 20% premium over its pre-offer trading price. Riot’s aggressive strategy is driven by recent industry dynamics and Bitfarms’ internal challenges, and it has the potential to profoundly impact the Bitcoin mining landscape.

Riot Platforms, already a major player in the Bitcoin mining sector, has taken a 9.25% stake in Bitfarms, making it the largest shareholder. This move follows Bitfarms’ management turmoil, including the firing of interim CEO Geoffrey Morphy, who is now suing the company for $27 million in damages. Riot’s initial offer, made on April 22, was rejected by Bitfarms’ board without substantive dialogue. Undeterred, Riot plans to call a shareholder meeting to appoint new independent directors, signaling a clear intention to influence Bitfarms’ strategic direction.

The proposed acquisition highlights a significant trend in the Bitcoin mining sector: consolidation. This trend has been accelerated by the recent Bitcoin “halving,” an event that occurs approximately every four years and cuts the rewards miners receive for validating transactions by 50%. This reduction in rewards tightens margins and pushes miners to either scale operations or seek consolidation to maintain profitability.

For Riot, absorbing Bitfarms would create the largest Bitcoin miner globally, based on projected computing power growth. This expansion would significantly enhance Riot’s Bitcoin production capabilities, positioning it alongside industry giants like Marathon Digital Holdings Inc. and CleanSpark Inc. The increased scale and capacity would provide Riot with greater negotiating power, more efficient operations, and improved resilience against market fluctuations and rising energy costs.

Riot’s pursuit of Bitfarms sends a clear message to other players in the Bitcoin mining space: scale is essential for survival and success in the post-halving era. Smaller miners, already struggling with reduced revenues and limited access to capital, may find it increasingly challenging to compete against larger, resource-rich companies. This could trigger a wave of mergers and acquisitions as miners seek to consolidate resources, optimize operations, and leverage economies of scale.

For instance, Bitcoin miner Stronghold Digital Mining Inc. is already exploring strategic alternatives, including a potential sale. As the industry adapts to the new economic realities imposed by the halving, more companies might follow suit, either by seeking mergers or becoming acquisition targets themselves.

The consolidation trend among Bitcoin miners has broader implications for the cryptocurrency industry. Firstly, it could lead to increased centralization of mining power, potentially raising concerns about the decentralization ethos of Bitcoin. However, it could also result in more efficient and stable mining operations, reducing the risk of disruptions and enhancing the overall security and reliability of the Bitcoin network.

Moreover, large-scale miners like Riot, with significant resources and capacity, are better positioned to adopt sustainable practices and negotiate favorable energy contracts, potentially addressing some of the environmental criticisms faced by the industry.

Riot Platforms’ bid to acquire Bitfarms marks a pivotal moment in the evolution of Bitcoin mining. This strategic move underscores the importance of scale in navigating the post-halving landscape and sets the stage for further consolidation in the industry. For investors and stakeholders in the cryptocurrency space, this development highlights the dynamic and competitive nature of Bitcoin mining, where agility, resources, and strategic vision are key to thriving in an ever-evolving market. As the industry continues to mature, the actions of major players like Riot will undoubtedly shape the future of cryptocurrency mining and its role within the broader financial ecosystem.

Take a moment to take a look at Bit Digital, a large-scale bitcoin mining business with operations across the U.S. and Canada.

Release – YS Biopharma Announces Name Change to LakeShore Biopharma

GAITHERSBURG, Md., May 24, 2024 /PRNewswire/ — YS Biopharma Co., Ltd. (Nasdaq: YS) (“YS Biopharma” or the “Company”), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced it is changing its legal name from “YS Biopharma Co., Ltd.” to “LakeShore Biopharma Co., Ltd”.

   

Dr. David Shao, Director, President, Co-Chief Executive Officer, and Chief Business Officer of the Company, commented, “We have decided to change our company name to LakeShore Biopharma to align with our global market positioning and international brand image. This change marks one of the first steps for us to expand our market reach, and we are eager to move forward and drive success under our new company name.”

The name change and trading symbol change will not affect any rights of shareholders or the Company’s operations and financial position. The Company’s ordinary shares and warrants will continue to be listed on the Nasdaq. Effective with the opening of the trading day on May 28, 2024, the ticker symbol of the Company’s ordinary shares and warrants will change from “YS” to “LSB” and from “YSBPW” to “LSBPW”, respectively. There is no action required by the Company’s current shareholders with respect to the company name or ticker symbol changes. The Company’s CUSIP will not change in connection with the name change.

About LakeShore Biopharma (formerly known as YS Biopharma)

LakeShore Biopharma, previously known as YS Biopharma, is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA® immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The Company operates in China, the United States, Singapore, and the Philippines, and is led by a management team that combines rich local expertise and global experience in the biopharmaceutical industry. For more information, please visit investor.ysbiopharma.com.

Investor Relations Contact

Alyssa Li
Director of Investor Relations
Email: ir@yishengbio.com

Robin Yang
Partner, ICR, LLC
Tel: +1 (212) 537-4035
Email: YSBiopharma.IR@icrinc.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ys-biopharma-announces-name-change-to-lakeshore-biopharma-302155079.html

SOURCE 

Ether ETFs Get Green Light, Ushering In New Era for Crypto Investing

The crypto world was abuzz this week as the U.S. Securities and Exchange Commission (SEC) gave the green light for the launch of exchange-traded funds (ETFs) that will track the price of ether, the cryptocurrency powering the Ethereum blockchain.

In a little-noticed release on Thursday evening, the SEC approved a rule change by the Chicago Board Options Exchange (CBOE) that effectively opens the door for ether ETFs to be listed and traded just like their bitcoin counterparts.

This landmark decision represents a major milestone for the crypto industry’s evolution into mainstream finance. It grants ether, after years of regulatory ambiguity, a legitimacy akin to that bestowed upon bitcoin last year when the first bitcoin ETFs hit the market.

“This is a huge development that really drives home ether’s commodity status from a regulatory perspective,” said Rachel Lin, CEO of crypto derivatives platform SynFutures. “It will allow investors, from retail to institutional, to gain exposure to ether through a regulated, familiar investment vehicle.”

Ether is the second-largest cryptocurrency after bitcoin with a market cap of around $220 billion. It has rapidly emerged as a crucial piece of infrastructure undergirding large swaths of crypto and blockchain applications beyond just a medium of exchange.

The Ethereum network hosts a multitude of decentralized apps and services, including large stablecoin ecosystems, decentralized finance (DeFi) platforms for lending/borrowing, and a rapidly expanding universe of blockchain-based games and metaverse projects. All these rely on ether as the “gas” that powers the network.

Major crypto companies quickly celebrated the ruling as catalyzing new growth for the ecosystem. “This approval from the SEC will allow millions of investors to embrace crypto in a familiar, regulated way,” said David Puth, CEO of cryptocurrency exchange CoinX.

The decision paves the way for asset managers to launch ether ETFs that directly hold the cryptocurrency, similar to existing bitcoin offerings like the Bitcoin ETF. This could drive significant new investment into ether from both institutional players seeking crypto exposure without holding the underlying asset, as well as retail investors who want a simple ether investment product available in traditional brokerage accounts.

However, some key questions remain around which specific ETF proposals will get approved, when they might begin trading, and whether they will be physically-backed with actual ether or employ indirect exposure through derivatives.

Leading ETF issuers like BlackRock, Fidelity, and WisdomTree have active filings for ether ETFs that could get a look. But smaller players like Cathie Wood’s Ark Invest were among the first movers on bitcoin ETF filings and could be better positioned for any initial ether product launches as well.

While the ether ETFs have a regulatory greenlight, they will still need to be approved on an individual basis by the SEC and the exchanges they list on. Industry analysts expect a speedy process, with the first launch potentially coming in the next few months.

For ether investors who have waited years for this moment, simple and convenient access to the world’s most actively utilized crypto network through traditional market infrastructure is almost at hand. The launch of ether ETFs may turbocharge investment into the Ethereum ecosystem – and accelerate the momentum behind crypto’s move into mainstream finance.

Want small cap opportunities delivered straight to your inbox?

Channelchek’s free newsletter will give you exclusive access to our expert research, news, and insights to help you make informed investment decisions.

Get Instant Access

Maple Gold Mines (MGMLF) – What is in Store for the Remainder of 2024?


Friday, May 24, 2024

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Drilling to resume later in the year. Maple Gold has been undertaking a systematic compilation and review of its technical database associated with its 400 square kilometer property package. Maple Gold’s technical team is nearing completion of a new three-dimensional litho-structural model to support a focused ranking and prioritization of property-wide drill targets to be tested later this year. Maple also initiated high resolution drone magnetic surveys in selected areas which will be completed in the second quarter of 2024.

Significant depth potential at Douay. The 2022 Douay mineral resource estimate addressed optimizing complementary open-pit and underground scenarios. Resources below the pit have significant potential for expansion given the limited amount of drilling below approximately 300 meters vertical depth. Deep drilling in 2023 confirmed continuity of the mineralized system at depth. Maple Gold intends to increase the underground gold resource to two million ounces largely by drilling near and below the base of the pit.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Euroseas (ESEA) – Results below expectations on higher drydocking costs but near-term outlook still bright.


Friday, May 24, 2024

Euroseas Ltd. was formed on May 5, 2005 under the laws of the Republic of the Marshall Islands to consolidate the ship owning interests of the Pittas family of Athens, Greece, which has been in the shipping business over the past 140 years. Euroseas trades on the NASDAQ Capital Market under the ticker ESEA. Euroseas operates in the container shipping market. Euroseas’ operations are managed by Eurobulk Ltd., an ISO 9001:2008 and ISO 14001:2004 certified affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. Euroseas employs its vessels on spot and period charters and through pool arrangements.

Michael Heim, Senior Vice President, Equity Research Analyst, Energy & Transportation, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Euroseas reported results below expectations mainly due to higher drydocking costs. Vessel utilization and shipping rates were near expectations. With ship repairs completed and new vessels on the way, the company is well positioned to take advantage of an improved shipping rate environment. While the existing fleet is largely chartered out, the addition of four newbuild vessels increases the company’s leverage to shipping rates. 

Management expects some shipping rate softness in 2025 due to the large number of vessel additions industry wide year to date. Shipping rates have benefitted from the conflict in the Red Sea, which has caused ships to take longer routes. Should conflicts abate, rates could weaken as decreased demand for ships is met with additional vessel supply. We would not be surprised to see management increase its 2025 charter position ahead of any weakness.

Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Behind the Scenes of Biotech’s Battle for the Billion-Dollar Diet Pill

For biotech investors scouring for the next big opportunity, the massive manufacturing expansions underway at pharma giant Eli Lilly (LLY) are worth a close look. The company just announced another staggering $5.3 billion investment into a key production facility in Indiana to crank up supply of its blockbuster obesity and diabetes drugs.

This commitment brings Lilly’s total investment at the Lebanon, Indiana site to an incredible $9 billion – representing the firm’s largest-ever manufacturing bet in its nearly 150-year history. It highlights the huge demand that Lilly’s game-changing medications like Mounjaro and Zepbound are facing from physicians and patients alike.

For small biotech firms developing the next generation of weight loss, diabetes and metabolism therapies, Lilly’s supply chain moves send an important signal – this market is headed for explosive growth in the coming years. Companies sitting on promising pipeline candidates could emerge as attractive buyout targets.

At the heart of Lilly’s expansion plans are its incretin drugs, which mimic gut hormones to suppress appetite and regulate blood sugar. Mounjaro, approved for diabetes, and Zepbound, greenlit for chronic weight management, both contain the active ingredient tirzepatide.

Since their launches, demand for these effective and convenient once-weekly injectable treatments has far outstripped supply. Shortages have been widespread in the U.S. as Lilly raced to build out its production infrastructure.

The new $9 billion Indiana campus will be instrumental in increasing Lilly’s capacity to manufacture tirzepatide at scale. When fully operational in 2028, it will employ around 900 skilled workers including scientists, engineers and technicians.

But this plant is just one piece of Lilly’s supply chain mobilization for incretin drugs. Since 2020, the company has plowed over $18 billion into building, acquiring and expanding manufacturing sites in the U.S. and Europe. New facilities are also coming online in North Carolina, Ireland and Germany through 2026.

These investments are already paying dividends. On its latest earnings call, Lilly hiked its 2023 revenue guidance by $2 billion, citing greater visibility into ramping up production of Mounjaro, Zepbound and its incretin pipeline over the remainder of the year.

For small biotechs, the supply chain frenzy at Lilly underscores the commercial opportunity in obesity, diabetes and metabolism. With over 40% of U.S. adults classified as obese, safe and effective chronic weight management regimens like Lilly’s incretin franchise could disrupt a massive global market worth billions annually.

Take a moment to look at more emerging growth biotechnology companies by taking a look at Noble Capital Markets’ Senior Research Analyst Robert LeBoyer’s coverage list.

The manufacturing expansions suggest appetite for these therapies will continue to surge, fueling demand for the next generation of medications offering better efficacy, tolerability and dosing schedules. Smaller drug developers operating in this space could become prime M&A candidates as deep-pocketed pharmas look to build out their obesity and diabetes portfolios.

Case in point: Lilly itself acquired Zepbound through its $8 billion buyout of Protunor Biopharma in 2022. Several major deals have already reshaped the incretin drug landscape in recent years, including Pfizer’s $6.7 billion purchase of Akero Therapeutics for its NASH/diabetes pipeline.

With its bold investments, Lilly is putting its money where its mouth is when it comes to obesity and metabolic disease. For lean biotechs advancing the next wave of therapies in this booming treatment category, that could spell opportunity knocking in the form of lucrative buyout offers or partnerships down the line.

Keep an eye on this space as Lilly’s supply chain moves underscore that the fight against fat is only just beginning for the pharmaceutical industry.

Trade Settlement Just Accelerated – What It Means for Your Money

If you trade stocks, bonds or other securities, a major change is coming next week that could significantly impact your transactions and capital. On May 28th, the settlement cycle for trades in U.S. markets is shifting from the longstanding T+2 standard down to T+1.

What does this mean? Instead of having two business days after a trade execution to pay up and settle, you’ll now need to pony up your cash and securities just one day later under the accelerated T+1 timeline.

While seemingly a small change, this compression in the settlement schedule could have big ramifications for how you manage trades and the money involved. The transition is expected to cause disruptions, at least in the short-term, that all investors need to be prepared for.

For one, market participants anticipate a spike in trade settlement failures as brokers, banks and trading firms scramble to comply with the tighter T+1 window. With less time to line up cash and shares, there is higher risk that obligations don’t get met when due. History shows failure rates did jump when the U.S. shifted from T+3 to T+2 settlement back in 2017.

Settlement failures can lead to losses on trades, penalties, and reputational damage. The Securities Industry and Financial Markets Association (SIFMA) expects “small changes” in fail rates initially, but any increase could create snags.

There are also concerns that risks and cash crunches could migrate to other areas like foreign exchange funding markets. Foreign investors holding trillions in U.S. securities may face challenges sourcing dollars for transactions in the compressed T+1 timeframe. This could drive demand for overnight lending at elevated interest rates.

Similarly, the shortened settlement cycle could disrupt securities lending by reducing the availability of shares to borrow if there is less time to recall loaned stocks before settling trades.

While ultimately aimed at reducing risks long-term, the shortened T+1 settlement period represents a monumental operational change that the investing industry has been scrambling to prepare for. Over 1,000 different firms have been coordinating testing, setting up monitoring “command centers”, and adjusting processes.

Even with months of planning, there could still be issues and errors in the first few days and weeks as standard practices adapt to the quicker timeline. Major transition risk points to watch include May 29th when trades from both the final T+2 date and first T+1 date converge, creating an expected settlement volume surge.

For all investors, some key implications are clear – be ready for potential trade failures and funding crunches, have contingency plans in place, and expect a Period of adjustment as the new accelerated T+1 regime takes hold. Flexibility and patience may be required as longstanding settlement processes are overhauled practically overnight.

The shift to T+1 is considered vital to modernizing market plumbing. But adapting to its faster payment cadence will put investors’ operational capabilities and capital management to the test like never before.

Want small cap opportunities delivered straight to your inbox?

Channelchek’s free newsletter will give you exclusive access to our expert research, news, and insights to help you make informed investment decisions.

Get Instant Access

Release – Traws Pharma’s ICAR Poster Highlights Potency Of COVID-19 Candidate

Research News and Market Data on TRAW

May 23, 2024

Differentiated resistance profile positions Traws’ program as a potential class leader

NEWTOWN, Pa., May 23, 2024 (GLOBE NEWSWIRE) — Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral diseases and cancer, today announced presentation of a poster at the annual International Conference on Antiviral Research (ICAR2024) which is being held from May 20th to May 24th in Gold Coast, Australia. The poster highlights positive results of preclinical experiments using patient isolates of COVID19 virus to define the resistance profile of ratutrelvir, formerly known as travatrelvir or TRX01, Traws’ ritonavir-free Mpro protease inhibitor for COVID19, currently in Phase 1 single and multiple ascending dose (SAD/MAD) escalation studies.

“We are very pleased to present the results of resistance studies for ratutrelvir at ICAR2024. Resistance studies are an important part of establishing a differentiation profile for an antiviral agent. Our initial data indicate that ratutrelvir has superior activity compared to nirmatrelvir against a range of omicron variants, based on a comparison of EC50. We believe the results presented at ICAR provide additional positive data to indicate that ratutrelvir has a differentiated resistance profile compared to nirmatrelvir,” said Werner Cautreels, Ph.D., Chief Executive Officer of Traws Pharma.

Dr. Cautreels continued, “Some resistance mutations are common to both drugs but a large part of resistance to nirmatrelvir was not seen with ratutrelvir. Together, ratutrelvir’s differentiated resistance profile, promising pharmacokinetic effects, potential to be used without ritonavir and the accelerated pace of Phase 1 enrollment put the compound on track to advance to Phase 2 studies in H2 2024 and position ratutrelvir as a potential class-leading therapy for COVID- 19.”

C. David Pauza, Ph.D., Chief Scientific Officer, Virology at Traws Pharma said, “Understanding the patterns of resistance mutations gives us the ability to identify circulating viruses that may already be resistant to individual antiviral agents; selecting the right drug can be guided by this information. The resistance studies presented at ICAR compared ratutrelvir to nirmatrelvir, the only Mpro inhibitor approved in the U.S. Our data suggest that ratutrelvir exhibited greater activity compared to nirmatrelvir against wild type Mpro, and remained active against Mpro variants with specific mutations that are associated with nirmatrelvir resistance.”

Dr. Pauza added, “An important finding was that critical mutations accounting for much of the resistance to nirmatrelvir were not found using ratutrelvir, indicating important differences between the two compounds. These differences were most apparent when the nirmatrelvir-resistant mutants P252L or T304I were involved in drug resistance, as these mutations were not observed after ratutrelvir selection.

The data were reported in a poster entitled, “Travatrelvir, an inhibitor of SARS-CoV-2 Main Protease now in Phase 1 Clinical Trials: in vitro Drug Resistance Compared to Nirmatrelvir” (Abstract 356V) presented at ICAR by Bhargava Teja Sallapalli, Master of Veterinary Science, Department of Veterinary Medicine, Virginia-Maryland School of Veterinary Medicine, College Park Maryland et al. The poster can be found on the Scientific Presentations section of the Traws Investor Relations web page.

About Ratutrelvir, the Phase 1 Program and Planned Next Steps

Ratutrelvir (also previously known as 83-0060) was designed as an inhibitor of the SARS-CoV-2 Mpro (3CL protease). It has demonstrated in vitro activity against the original strain of the virus as well as the delta and omicron variants and is more active than nirmatrelvir (PAXLOVID®, Pfizer’s Mpro inhibitor) in preclinical studies. Also in preclinical studies, ratutrelvir did not require co-administration with a human cytochrome P450 (CYP) inhibitor, such as ritonavir, and so it is expected to avoid associated drug:drug interactions, potentially permitting wider patient use. The drug candidate’s pharmacokinetic (PK) profile may enable a once daily, treatment regimen and reduce the likelihood of viral rebound.

The Phase 1 study will evaluate single and multiple ascending doses of ratutrelvir in a double-blinded, placebo-controlled clinical trial to assess safety, tolerability, and pharmacokinetics. Subjects will be randomized 3:1 in five fasted and one fed single ascending dosing (SAD) cohorts and two multiple ascending dosing (MAD) cohorts. Topline data from the study, which is being conducted in Australia (NCT06402136), and the initiation of an international Phase 2 study in subjects with moderate to severe COVID19, are expected to take place in H2 2024.

About Traws Pharma, Inc.

Traws Pharma is a clinical stage biopharmaceutical company developing oral small molecule therapies for the treatment of respiratory viral diseases and cancer. The viral respiratory disease program includes an oral inhibitor of the SARS-CoV-2 Mpro (3CL protease), ratutrelvir, and tivoxavir marboxil, a new oral antiviral drug candidate for influenza which targets the influenza cap-dependent endonuclease and has shown activity in cell-based assays against drug resistant viruses as well as against avian flu.

In the cancer program, Traws is developing the novel, proprietary multi-kinase CDK4-plus inhibitor narazaciclib for refractory endometrial cancer and potentially other cancers. Narazaciclib targets pathways involved in the development of resistance to CDK inhibitors.

Traws Pharma is committed to delivering novel compounds for unmet medical needs using state-of-the-art drug development technology. With a focus on product safety and a commitment to patients in need or that are specifically vulnerable, we build solutions for important medical challenges, aiming to alleviate the burden of viral infections and cancer.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties including statements regarding preclinical studies to evaluate the resistance profile of ratutrelvir, the Phase 1 study of ratutrelvir in Australia and its design, timing and potential results and the timing of a planned Phase 2 study. Traws has attempted to identify forward-looking statements by terminology including “believes”, “estimates”, “anticipates”, “expects”, “plans”, “intends”, “may”, “could”, “might”, “will”, “should”, “preliminary”, “encouraging”, “approximately” or other words that convey uncertainty of future events or outcomes. Although Traws believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including the success and timing of Traws’ clinical trials, collaborations, market conditions and those discussed under the heading “Risk Factors” in Traws’ filings with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Traws undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Traws Pharma, Inc. Contact:
Mark Guerin
Traws Pharma, Inc.
267-759-3680
www.trawspharma.com

Investor Contact:
Bruce Mackle
LifeSci Advisors, LLC
646-889-1200
bmackle@lifesciadvisors.com